2-chloro-4-(4-pyridyl)-pyrimidine | 208936-45-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-chloro-4-(4-pyridyl)-pyrimidine
• 英文别名: 2-Chloro-4-(pyridin-4-yl)pyrimidine；2-chloro-4-pyridin-4-ylpyrimidine
• CAS: 208936-45-2
• 化学式: C₉H₆ClN₃
• 分子量: 191.62
• InChiKey: DBWZTBFSHQDFHR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-chloro-4-(4-pyridyl)-pyrimidine 在 吡啶 、 一水合肼 作用下， 反应 16.0h， 生成 2-hydrazinyl-4-(4-pyridinyl)pyrimidine
  参考文献：
  名称：

  [EN] HERBICIDAL COMPOUNDS
  [FR] COMPOSÉS HERBICIDES

  摘要：

  式(I)的化合物，其中取代基如权利要求1所定义，作为杀虫剂特别是除草剂时有用。

  公开号：

  WO2021058595A1
• 作为产物：
  描述：

  lithium,4H-pyridin-4-ide 、 2-氯嘧啶 在 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 乙醚 、 四氢呋喃 为溶剂， 生成 2-chloro-4-(4-pyridyl)-pyrimidine
  参考文献：
  名称：

  Hit to lead studies on (hetero)arylpyrimidines—Agonists of the canonical Wnt-β-catenin cellular messaging system

  摘要：

  A series of (hetero)arylpyrimidines agonists of the Wnt-beta-catenin cellular messaging system have been prepared. These compounds show activity in U2OS cells transfected with Wnt-3 alpha, TCF-luciferase, Dkk-1 and tk-Renilla. Selected compounds show minimal GSK-3 beta inhibition indicating that the Wnt-beta-catenin agonism activity most likely comes from interaction at Wnt-3 alpha/Dkk-1. Two examples 1 and 25 show in vivo osteogenic activity in a mouse calvaria model. One example 1 is shown to activate non-phosphorylated beta-catenin formation in bone. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.10.093

文献信息

• Substituted pyrimidine compounds and methods of use
  申请人：Amgen Inc.

  公开号：US20030069425A1

  公开（公告）日：2003-04-10

  Selected novel substituted pyrimidine compounds are effective for prophylaxis and treatment of diseases, such as TNF-&agr;, IL-1&bgr;, IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving inflammation, pain, diabetes and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选择的新型代替嘧啶类化合物可用于预防和治疗诸如TNF-α、IL-1β、IL-6和/或IL-8介导的疾病，以及其他疾病，如疼痛和糖尿病。该发明涵盖了新型化合物、类似物、前药及其药学上可接受的盐、制药组合物和用于预防和治疗涉及炎症、疼痛、糖尿病等疾病和其他疾病或病况的方法。该发明还涉及制备这种化合物的过程，以及在这些过程中有用的中间体。
• Substituted pyrimidine compounds and their use
  申请人：AMGEN INC.

  公开号：EP1314731A2

  公开（公告）日：2003-05-28

  Selected novel substituted pyrimidine compounds are effective for prophylaxis and treatment of diseases, such as TNF-α, IL-1β, IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving inflammation, pain, diabetes and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  精选的新型取代嘧啶化合物可有效预防和治疗疾病，如TNF-α、IL-1β、IL-6和/或IL-8介导的疾病，以及其他疾病，如疼痛和糖尿病。本发明包括新型化合物、类似物、原药及其药学上可接受的盐、药物组合物以及用于预防和治疗涉及炎症、疼痛、糖尿病等疾病和其他弊病或病症的方法。本发明还涉及制造此类化合物的工艺以及在此类工艺中有用的中间体。
• SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE
  申请人：Amgen inc.

  公开号：EP0948497A2

  公开（公告）日：1999-10-13
• US6410729B1
  申请人：——

  公开号：US6410729B1

  公开（公告）日：2002-06-25
• US6610698B2
  申请人：——

  公开号：US6610698B2

  公开（公告）日：2003-08-26